Oral Arsenic Trioxide Composition Dissolution Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing oral arsenic trioxide compositions are costly, complex, and inefficient, with low solubility in water and no USFDA-approved oral formulations available, necessitating a more economical and industrially feasible process with improved dissolution profiles.
Innovation Solution
Development of an oral pharmaceutical composition of arsenic trioxide in the form of capsules, tablets, or granules using pharmaceutically acceptable excipients like diluents, binders, lubricants, and surfactants, prepared through wet granulation, spray drying, or rotary evaporator processes, ensuring at least 80% arsenic trioxide release within 45 minutes without lyophilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If lyophilization is used to prepare oral arsenic trioxide composition, then dissolution profile is improved, but manufacturing cost increases and process complexity increases
Solution Approach 1:
The invention extracts and eliminates the lyophilization step from the manufacturing process, replacing it with a simpler formulation approach that achieves comparable dissolution profiles without the complex equipment and processes required for freeze-drying
Solution Approach 2:
The invention changes the formulation parameters by incorporating specific excipients and adjusting the physical-chemical properties of the oral composition, thereby achieving improved dissolution without requiring lyophilization processing
2Object-affected harmful factors
If arsenic trioxide is administered orally, then QT interval prolongation and ventricular tachycardia are reduced, but peak plasma concentration is lower
Solution Approach 1:
The invention modifies the formulation parameters including pH-adjusting agents and surfactants to optimize the dissolution and absorption characteristics of arsenic trioxide, achieving a balance between reduced cardiotoxicity and adequate plasma concentration
Solution Approach 2:
The invention creates a composite oral formulation combining arsenic trioxide with multiple excipients including pH-adjusting agents, surfactants, and other pharmaceutically acceptable materials to enhance bioavailability while reducing harmful effects
3Quantity of substance
If arsenic trioxide is administered intravenously, then peak plasma concentration is higher, but QT interval prolongation and ventricular tachycardia increase
Solution Approach 1:
The invention introduces an oral formulation as an intermediary route of administration that mediates between the high peak concentration of IV administration and the reduced efficacy of simple oral dosing, achieving therapeutic效果 with reduced cardiotoxicity
Solution Approach 2:
The invention changes the administration route and formulation parameters to achieve a more favorable pharmacokinetic profile with reduced peak plasma concentrations and associated cardiotoxic effects
4Ease of manufacture
If conventional processes are used to prepare oral arsenic trioxide, then manufacturing is simpler, but dissolution profile is poor and cost-effectiveness is reduced
Solution Approach 1:
The invention optimizes formulation parameters including the use of pH-adjusting agents, surfactants, and specific excipients to achieve improved dissolution profiles through conventional manufacturing processes without requiring complex equipment or procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new process provides a cost-effective, efficient, and industrially viable oral arsenic trioxide composition with enhanced dissolution profiles, meeting regulatory standards and effectively treating acute promyelocytic leukemia and other cancers.
Implementation Method 1
The oral composition can be prepared by wet granulation process (such as fluid bed processor or rapid mixer granulator)
Implementation Method 2
The oral composition can be prepared by spray drying process
Implementation Method 3
The oral composition can be prepared by rotary evaporator
Data Source
AI summary
The present invention provides oral pharmaceutical composition comprising Arsenic trioxide and one or more pharmaceutically acceptable excipients for use in the treatment of acute promyelocytic leukemia and other cancers like acute myeloid leukemia. Further, the present invention provides a process for the preparation of the said composition.